Form 4: Southpoint Capital Sells Fennec Pharma Shares

Southpoint Capital Advisors LP, a 10% owner, reported the sale of 1,000,000 shares of Fennec Pharmaceuticals Inc. common stock for $7.50 per share.

Summary

• Southpoint Capital Advisors LP, identified as a 10% owner of Fennec Pharmaceuticals Inc. (FENC), disposed of 1,000,000 shares of common stock.
• The transaction occurred on December 24, 2025, with shares sold at a price of $7.50 per share.
• Following this disposition, Southpoint Capital Advisors LP, through Southpoint Master Fund, LP, beneficially owns 2,744,741 shares of Fennec Pharmaceuticals Inc.
• The sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Multiple entities and individuals are listed as reporting persons, including Southpoint Capital Advisors LLC, Southpoint GP, LP, Southpoint GP, LLC, and John S. Clark II, all disclaiming beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 3

Explanation: The sale of 1,000,000 shares by a 10% owner and director is generally perceived negatively by the market, indicating a reduction in insider confidence or a portfolio rebalancing, despite being part of a 10b5-1 plan.

Negatives

• A significant 10% owner and director, Southpoint Capital Advisors LP, sold 1,000,000 shares of Fennec Pharmaceuticals Inc. common stock.
• This disposition reduces their beneficial ownership to 2,744,741 shares, potentially signaling a reduction in insider confidence.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context but reflects a specific investment decision by a significant shareholder.

Related Party Transactions

• The sale of 1,000,000 shares of Fennec Pharmaceuticals Inc. common stock by Southpoint Capital Advisors LP, a 10% owner and director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the significant sale by a 10% owner and director as a potential lack of confidence in the company's future prospects, which could lead to negative sentiment and downward pressure on the stock price.

Key Dates

Recommendation

The disposition of 1,000,000 shares by Southpoint Capital Advisors LP, a 10% owner and director, suggests a significant reduction in insider confidence or a strategic portfolio adjustment away from Fennec Pharmaceuticals. Such a large insider sale, even if pre-planned, typically signals potential headwinds or a belief that the stock is fully valued, warranting a 'sell' recommendation for investors.

Keywords

Fennec Pharmaceuticals, FENC, Southpoint Capital Advisors, Insider Sale, Form 4, Stock Transaction, 10b5-1 Plan, Beneficial Ownership